United Therapeutics (UTHR) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenues of $715 million, up 20% year-over-year, driven by strong growth in Tyvaso, Orenitram, Remodulin, and Unituxin, and supported by commercial execution and innovation in drug-device combinations.

• Net income for Q2 2024 was $278.1 million, up from $259.2 million in Q2 2023, with diluted EPS rising to $5.85 from $5.24.

• Strategic focus includes current market-leading products, next-generation therapies in late-stage trials, and organ manufacturing for end-stage disease.

• Completed a $1.0 billion accelerated share repurchase, reducing outstanding shares and returning capital to shareholders.

• Continued investment in R&D, including organ manufacturing and late-stage clinical trials for Tyvaso and ralinepag.

Financial highlights

• Q2 2024 revenues reached $715 million, up 20% year-over-year; net income was $278.1 million; diluted EPS was $5.85.

• Tyvaso revenue was $398.2 million, up 25% year-over-year, driven by DPI uptake, pricing, and increased utilization.

• Orenitram revenue hit $107.1 million, up 13% year-over-year, with growth from utilization, pricing, and higher average dose.

• Remodulin revenue was $147.3 million, up 16% year-over-year, maintaining leadership in parenteral prostacyclin.

• Unituxin revenue reached $51.7 million, up 17% globally and 18% in the US, driven by price and volume.

Outlook and guidance

• Anticipates near-term revenue growth driven by Tyvaso DPI, increased PH-ILD patient adoption, and Orenitram.

• Confident in durable growth profile for Tyvaso franchise, supported by record referrals and starts.

• Ongoing focus on late-stage clinical trials (TETON for IPF, Ralinepag for PAH) with high potential to double revenue run rate if successful.

• Budgeted $575 million in capital expenditures through 2026, mainly for Tyvaso DPI manufacturing expansion.

• IRA-related Medicare Part D changes may impact Tyvaso DPI and Orenitram revenues, with some offset from increased patient access.